Ticagrelor Lowers the Risk for OA Compared with Clopidogrel
In this study, treatment with ticagrelor was associated with a 29% lower risk of developing OA than treatment with clopidogrel over five years of follow-up. (Source: The Rheumatologist)
Source: The Rheumatologist - October 28, 2020 Category: Rheumatology Authors: Arthritis & Rheumatology Tags: Conditions Osteoarthritis Arthritis & Rheumatology clopidogrel ticagrelor Source Type: research

FDA Warning: Avoid Use of NSAIDs after Week 20 of Pregnancy
The FDA is recommending pregnant women avoid using NSAIDs as early as week 20 of pregnancy due to the risk of kidney problems in an unborn fetus. (Source: The Rheumatologist)
Source: The Rheumatologist - October 28, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Safety FDA kidney oligohydramnios pregnancy Renal safety warning U.S. Food and Drug Administration (FDA) Source Type: research

Gout: The State of the Science
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few: (Source: The Rheumatologist)
Source: The Rheumatologist - October 26, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Crystal Arthritis ACR Convergence 2020 – Gout Source Type: research

Commensal Cross-Reactive T & B Cells Trigger Autoimmunity
Researchers are finding that antigens from the microbiota may play a role in the development of autoimmunity. (Source: The Rheumatologist)
Source: The Rheumatologist - October 26, 2020 Category: Rheumatology Authors: Kurt Ullman Tags: Conditions Antiphospholipid Syndrome APS Microbiome microbiota Source Type: research

New Regulation Would Eliminate ‘Duration of Status’ for Physicians with J-1 Visas
The Immigrations and Customs Enforcement (ICE) Bureau issued a notice of proposed rulemaking on Sept. 25 that would change the admission period of academic student and exchange visitor aliens, as well as representatives of foreign information media, from duration of status to an admission for a fixed time period.1 This would force all nonimmigrants in... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 24, 2020 Category: Rheumatology Authors: Keri Losavio Tags: Legislation & Advocacy Professional Topics J-1 visa Source Type: research

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis
The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis... (Source: The Rheumatologist)
Source: The Rheumatologist - October 21, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics & Biosimilars Drug Updates FDA approval Golimumab Pediatric polyarticular juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis (JIA) psoriatic arthritis U.S. Food and Drug Administration (FDA) Source Type: research

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model
A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to cate­gorize two main groups of symptoms into type 1, typically... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 20, 2020 Category: Rheumatology Authors: Catherine Kolonko Tags: Conditions Research Reviews SLE (Lupus) fatigue lupus disease model lupus subtypes Source Type: research

Hand Pain Depends on More Than Osteoarthritis Severity & Psych Profile
Pain is the main reason patients with osteoarthritis (OA) seek medical help because of the substantial burden it imposes and its impact on quality of life. Pain can actually change the way the central nervous system works. This central sensitization results in more pain with less provocation. And according to results from an observational study... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Thomas R. Collins Tags: Conditions Osteoarthritis Research Reviews arthritis pain hand pain Pain Management Source Type: research

Rheum After 5: Dr. George Tsokos Shares His Love & Friendship with a Cat
George C. Tsokos, MD, professor of medicine at Harvard Medical School and chief of the Division of Rheumatology, Beth Israel Deaconess Medical Center, both in Boston, doesn’t recall the moment he first became infatuated with Little, a 12-year-old Siamese cat. Dr. Tsokos doesn’t even own Little. Not that anyone can truly own any living creature.... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Carol Patton Tags: Profiles Rheum After 5 Dr. George C. Tsokos Source Type: research

Fall 2020 ’s Awards, Appointments & Announcements in Rheumatology
S. Louis Bridges Jr., MD, PhD, Moves to New York S. Louis Bridges Jr., MD, PhD, became the new physician in chief and chair of the Department of Medicine, Hospital for Special Surgery (HSS), New York, on Sept. 1. He will also serve as the chief of rheumatology at Weill Cornell College of Medicine. Prior... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Gretchen Henkel Tags: Awards Profiles Dr. Kenneth Saag Dr. Rebecca Manno Dr. S. Louis Bridges Jr. Movers & Shakers Source Type: research

Race As a Risk Factor for Sj ögrens Syndrome
A new study in Arthritis Care & Research highlights potential differences in incidence, the presentation of prominent symptoms and laboratory findings in African Americans and Native Americans with Sjögren’s syndrome compared with white populations. Native Americans appear to be at higher risk of the disease, although they often display fewer of the classic symptoms. Importantly,... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Ruth Jessen Hickman, MD Tags: Conditions Home Slider Research Reviews Systemic Inflammatory Syndromes racial disparities Risk Factors Sjögren's syndrome Source Type: research

Researchers Seek ANCA-Associated Vasculitis Subtype Markers
New research on complement activation in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis underscores its important role in the patho­genesis of this disease, an autoimmune condition defined by inflammation of small- and medium-caliber blood vessels.1 ANCA testing is commonly performed to help diagnose granulomatosis with polyangiitis and microscopic polyangiitis, both of which are forms of ANCA-associated... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Larry Beresford Tags: Conditions Vasculitis avacopan Biomarkers complement activation eculizumab Source Type: research

Rheumatology Health Educators Educate & Empower Patients
As a health educator at Integrative Rheumatology, a private practice in Charlotte, N.C., Latisha Williams, MPH, CHES, CHC, works with patients to teach them how to better manage their disease. In the two-and-a-half years that Ms. Williams has worked at Integrative Rheumatology, she’s answered countless questions about exercise, nutrition and complementary therapies, among other topics. “Patients... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Linda Childers Tags: Patient Perspective Practice Management Association of Rheumatology Professionals (ARP) health education patient education Source Type: research

The History of the American College of Rheumatology Image Library
Late-night gatherings; long hours of avid discussion weighing the merits of resolution quality, light, hues and tones; and camaraderie among members forged through a shared interest in maintaining the highest fidelity to their craft and profession—these are among the vivid memories of those who participated in the early years of building what is today known... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Mary Beth Nierengarten Tags: Electronic Health Records From the College Technology ACR Image Library images Rheumatology Image Bank Source Type: research

Reflections on Starting a Rheumatology Fellowship During the Pandemic
Some have opined, cynically, that transformative changes will not come to medical education and training, and to healthcare, until pigs fly. Well, in 2009–10, “swine flu,” and now we are in the midst of an unprecedented and disruptive pandemic, affecting virtually all aspects of our lives, including fellowships.1 As someone who started a rheumatology fellowship... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Nicole K. Zagelbaum Ward, DO, MPH, with Richard S. Panush, MD, MACP, MACR Tags: Education & Training Professional Topics Fellows-in-Training Source Type: research

A New Frailty Index Aids Lupus Assessment
A recently developed frailty index may be a valuable way to quantify vulnerability in patients with systemic lupus erythe­matosus (SLE), according to a study published in Arthritis & Rheumatology.1 When evaluating SLE, physicians consider a patient’s disease activity, organ damage and health-related quality of life. The Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index (SDI)... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Vanessa Caceres Tags: Conditions Research Reviews SLE (Lupus) frailty index Source Type: research

Advocating for Change: Q & A with Georgia State Rep. Kim Schofield
Rep. Kim Schofield’s path to the Georgia House of Representatives started with her lupus diagnosis 20 years ago. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Kimberly Retzlaff Tags: Legislation & Advocacy Lupus Representative Kim Schofield Source Type: research

UHC Updates Rituximab Policy to Require Use of Biosimilars
As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: From the College Tags: Billing/Coding biosimilar substitution non-medical switching prior authorization rituximab rituximab-abbs UnitedHealthCare (UHC) Source Type: research

ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions
The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Mary Beth Nierengarten Tags: American College of Rheumatology Dr. Chris Phillips Dr. Douglas White Institute for Clinical and Economic Review (ICER) Lupus nephritis Source Type: research

RheumPAC Kicks Off November Matching Campaign
RheumPAC will once again conduct a matching campaign in November, coinciding with ACR Convergence 2020. During this time, all donations to RheumPAC will be amplified by leaders from the College, who will match various dollar amounts for each contribution. Additionally, many will donate a larger amount for first-time investors. Last year, matching funds contributed $91... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: From the College Tags: Legislation & Advocacy RheumPAC match campaign Source Type: research

ACR Convergence 2020 Workshop Covers 2021 Practice Management & Coding Changes
Attendees at the daylong workshop will learn about key evaluation and management code changes coming in 2021 that affect rheumatologists and rheumatology professionals. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Mary Beth Nierengarten Tags: ACR Convergence Billing/Coding ACR Convergence 2020 E/M Coding Practice Management Source Type: research

Bring Quality Measures into Focus at ACR Convergence 2020
A panel of rheumatologists will provide updates on MACRA’s quality measure requirements and the ACR’s progress in quality measurement in rheumatology in a session at ACR Convergence 2020. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Vanessa Caceres Tags: ACR Convergence Quality Assurance/Improvement ACR Convergence 2020 Quality Measures Rheumatology Informatics System for Effectiveness (RISE) Registry Source Type: research

Effective ≠ Efficient: A Conversation with Dr. Alan Baer
From conducting a complete physical exam to writing case reports, Alan Baer, MD, believes that physicians can strive to be effective clinicians at any age. Here are some meaningful insights into his rheumatology career and treatment philosophy. (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2020 Category: Rheumatology Authors: Jason Liebowitz, MD Tags: Professional Topics Alan Baer Clinical Practice Mentor physical exam Source Type: research

Pregnancy Complications in Patients with Lupus & APS
Pregnancy complications are common in lupus and antiphospholipid syndrome (APS), but can we predict and prevent them? The Rheumatology Research Foundation Memorial Lectureship to Honor Shaun Ruddy, MD, will review the predictors and mechanisms of pregnancy complications, as well as potential interventions for preventing pregnancy complications associated with lupus and APS. Watch for it on... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Meeting Reports ACR Convergence 2020 - SLE Source Type: research

Lupus Nephritis: New Decade, New Approaches
This session at ACR Convergence will focus on early biomarkers for diagnostic and prognostic purposes, as well as the description of current treatment guidelines from multiple societies. The speakers will discuss the role of repeated biopsy to assess response and maintenance therapy, and describe some promising new therapies under development. Watch for it on Sunday,... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Meeting Reports 2020 ACR Convergence ACR Convergence 2020 - SLE Source Type: research

The Great Debate at ACR Convergence 2020: Should Jakinibs Be Used Before Biologics for RA?
The 2015 ACR guideline for RA treatment specifies that TNF inhibitors should be used before JAK inhibitors (jakinibs) for the treatment of RA when a patient fails to have an adequate response to conventional DMARDs. However, emerging data indicate that jakinibs may be even more effective than TNF inhibitors. Is it time to revisit this... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Meeting Reports ACR Convergence 2020 – RA Source Type: research

Pain in RA and OA: ACR Convergence 2020 Preview
Patients with RA and OA have joint pain, and pain is the primary reason patients seek care. The mechanisms responsible for the pain are now just beginning to be understood. This session, on Nov. 6, 4 p.m. EST, will cover the mechanisms responsible for the development of pain in both inflammatory and degenerative arthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Meeting Reports ACR Convergence 2020 – RA Source Type: research

Racial Disparity in RA & OA: ACR Convergence 2020 Preview
Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence Meeting Reports ACR Convergence 2020 – RA Source Type: research

Familial Patterns in Childhood- & Adult-Onset SLE
A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors. (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Kurt Ullman Tags: Conditions SLE (Lupus) childhood-onset SLE family genetic Pediatric systemic lupus erythematosus (SLE) Source Type: research

Ultrasound Provides Insights into Immune Checkpoint Inhibitor ‐Induced Inflammatory Arthritis
Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 12, 2020 Category: Rheumatology Authors: Elizabeth Hofheinz, MPH, MEd Tags: Conditions ACR Open Rheumatology ICI‐induced inflammatory arthritis immune checkpoint inhibitor (ICI) Immune checkpoint inhibitors Ultrasound Source Type: research

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 9, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: DMARDs & Immunosuppressives Drug Updates FDA polyarticular juvenile idiopathic arthritis (JIA) Tofacitinib U.S. Food and Drug Administration (FDA) Source Type: research

FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction
The FDA is requiring all benzodiazepines to carry an updated boxed warning that addresses the risks of misuse, abuse and addiction associated with their use. (Source: The Rheumatologist)
Source: The Rheumatologist - October 7, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Safety abuse Addiction benzodiazepines FDA safety warning U.S. Food and Drug Administration (FDA) Source Type: research

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 7, 2020 Category: Rheumatology Authors: Larry Beresford Tags: DMARDs & Immunosuppressives Drug Updates JAK inhibitors jakinib Rheumatoid Arthritis (RA) TNF inhibitors Tofacitinib Source Type: research

Hardship Exception Applications Open for Clinicians Struggling with Quality Payment Program Reporting in 2020
The Centers for Medicare & Medicaid Services have provided the opportunity to apply for exceptions for the Performance Year (PY) 2020 Quality Payment Program Merit-Based Incentive Program (MIPS) program requirements. This will help clinicians finding PY2020 MIPS federal reporting difficult due to circumstances outside their control. (Source: The Rheumatologist)
Source: The Rheumatologist - October 6, 2020 Category: Rheumatology Authors: From the College Tags: Quality Assurance/Improvement COVID-19 hardship exception Merit-Based Incentive Payment System (MIPS) Quality Payment Program (QPP) Source Type: research

Hardship Exception Applications Available for Clinicians Struggling with Federal Reporting in 2020
The Centers for Medicare & Medicaid Services have provided the opportunity to apply for exceptions for the Performance Year (PY) 2020 Quality Payment Program Merit-Based Incentive Program (MIPS) program requirements. This will help clinicians finding PY2020 MIPS federal reporting difficult due to circumstances outside their control. (Source: The Rheumatologist)
Source: The Rheumatologist - October 6, 2020 Category: Rheumatology Authors: From the College Tags: Quality Assurance/Improvement COVID-19 hardship exception Merit-Based Incentive Payment System (MIPS) Quality Payment Program (QPP) Source Type: research

UHC Announces New Copay Accumulator Policy Affecting In-Office Treatments
UnitedHealthcare (UHC) announced that, as of Jan. 1, 2021, providers will be required to report the amount their patients receive in copay assistance for office-administered treatments. UHC will then use this information to enforce a copay accumulator, ensuring that no copay assistance funds are applied toward patients’ deductibles or out-of-pocket maximum payments. The ACR has... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 6, 2020 Category: Rheumatology Authors: From the College Tags: Practice Management Advocacy copay accumulators UnitedHealthCare (UHC) Source Type: research

Find Solutions to Navigate Telerheumatology in Your Practice
Experts weigh in on sustaining telerheumatology as a viable practice tool by sharing its history, potential and regulatory outlook post-pandemic at ACR Convergence 2020. (Source: The Rheumatologist)
Source: The Rheumatologist - October 2, 2020 Category: Rheumatology Authors: Carina Stanton Tags: ACR Convergence 2020 ACR Convergence Dr. Chris Phillips Dr. Christine Peoples telemedicine Source Type: research

ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues
Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts. (Source: The Rheumatologist)
Source: The Rheumatologist - October 2, 2020 Category: Rheumatology Authors: Vanessa Caceres Tags: ACR Convergence 2020 ACR Convergence Advocacy Blair Solow Zachary Wallace Source Type: research

ACR Urges Commercial Payers to Cover Telemedicine Beyond the Public Health Emergency
In a letter sent to commercial payers, the ACR’s Insurance Subcommittee is advocating for continued coverage for telemedicine, including reimbursement parity, after the end of the declared public health emergency. (Source: The Rheumatologist)
Source: The Rheumatologist - October 2, 2020 Category: Rheumatology Authors: From the College Tags: Legislation & Advocacy Practice Management ACR Insurance Subcommittee (ISC) COVID-19 telemedicine Source Type: research

RheumPAC Hosts Rep. Kim Schrier, MD, for Legislative Update
RheumPAC donors attended a virtual legislative update and Q&A with former pediatrician Rep. Kim Schrier, MD (D-Wash.), to gain an insider’s view of current healthcare legislation. (Source: The Rheumatologist)
Source: The Rheumatologist - October 2, 2020 Category: Rheumatology Authors: From the College Tags: Legislation & Advocacy Kim Schrier RheumPAC Source Type: research

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing... (Source: The Rheumatologist)
Source: The Rheumatologist - October 1, 2020 Category: Rheumatology Authors: Ruth Jessen Hickman, MD Tags: Drug Updates Osteoarthritis Arthritis & Rheumatology fasinumab Knee Osteoarthritis (OA) Nerve growth factor (NGF) tanezumab Source Type: research

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate. (Source: The Rheumatologist)
Source: The Rheumatologist - October 1, 2020 Category: Rheumatology Authors: Arthritis & Rheumatology Tags: DMARDs & Immunosuppressives Drug Updates Arthritis & Rheumatology jakinib Methotrexate monotherapy Rheumatoid Arthritis (RA) upadacitinib upadacitinib monotherapy Source Type: research

Oxford University to Study Adalimumab as Potential COVID-19 Treatment
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 30, 2020 Category: Rheumatology Authors: Josephine Mason & Kate Kelland Tags: DMARDs & Immunosuppressives Drug Updates adalimumab COVID-19 Source Type: research

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution
In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain. (Source: The Rheumatologist)
Source: The Rheumatologist - September 30, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates ankylosing spondyl­itis Ankylosing spondylitis (AS) FDA Pain Pain Management tramadol hydrochloride U.S. Food and Drug Administration (FDA) upadacitinib Source Type: research

The Environment Within: A Possible Link Identified Between Plasma Microbial Translocation & Autoantibody Development in 1st Degree Relatives of SLE Patients
Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls. (Source: The Rheumatologist)
Source: The Rheumatologist - September 30, 2020 Category: Rheumatology Authors: Kurt Ullman Tags: Conditions SLE (Lupus) Arthritis & Rheumatology gut microbial translocation systemic lupus erythematosus (SLE) Source Type: research

Arthroscopic Partial Meniscectomy Tied to Radiographic Knee OA
(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 29, 2020 Category: Rheumatology Authors: By Lisa Rapaport Tags: Conditions Osteoarthritis knee Knee Osteoarthritis (OA) meniscal tear meniscectomy Pain Source Type: research

State of the Art: Lupus —the Future Is Now
Sunday, Nov. 8, 2020, 10–11:00 a.m. EST: Several lupus trials this past year had positive results, bringing hope that new therapeutics may be available in the near future. This session will discuss how advances in our understanding of lupus pathogenesis have led to the development of different therapeutic strategies. Watch this page for our report... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 28, 2020 Category: Rheumatology Authors: Keri Losavio Tags: ACR Convergence SLE (Lupus) ACR Convergence 2020 ACR Convergence 2020 - SLE Source Type: research

PCSK9 Inhibitors May Lower Cholesterol in Patients with Statin-Associated Immune-Mediated Necrotizing Myopathy
A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy... (Source: The Rheumatologist)
Source: The Rheumatologist - September 23, 2020 Category: Rheumatology Authors: Vanessa Caceres Tags: Drug Updates Arthritis & Rheumatology cholesterol immune-mediated necrotizing myopathy PCSK9 inhibitors protein convertase subtilisin/kexin type 9 inhibitors statin-associated myopathy Source Type: research

Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients
(Reuters Health)—Intravenous belimumab combined with standard lupus therapy can help preserve kidney function in patients with active lupus nephritis and cut the odds of death or a renal-related event by half, a phase 3 multinational study has concluded.1 After two years of therapy, 43% of 224 volunteers getting the drug monthly showed a renal response... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 21, 2020 Category: Rheumatology Authors: Reuters Staff Tags: Drug Updates belimumab kidney Lupus nephritis SLE systemic lupus erythematosus (SLE) Source Type: research

Polymyalgia Rheumatica Rapid Symptom Improvement After Glucose Is Controlled
(Reuters Health)—In a case series report, researchers describe rapid symptom improvement in three patients with polymyalgia rheumatica (PMR) when high glucose levels were brought down. After glucose was controlled, patients experienced improvement in both symptoms and laboratory measures of PMR without glucocorticoid administration or an increase in glucocorticoid dosage, according to the report in the... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 21, 2020 Category: Rheumatology Authors: Linda Carroll (with a commentary from rheumatologist Eric Matteson, MD) Tags: diabetes glucose polymyalgia rheumatica (PMR) type II diabetes Source Type: research